Are Genomic Studies Redefining Pancreatic Cancer?

A new study assessing chromosomal disruptions in pancreatic cancer according to the type of genetic chaos suggests that pancreatic cancer can be divided into 4 subgroups.

Pancreatic cancer is among the most difficult cancers to treat. Fewer than %5 of patients survive longer than 5 years. This new classification is hoped to enable progress in treating pancreatic cancer, perhaps one of the most challenging cancers to treat.

In this new study published in the world-renowned journal Nature, variations across the entire DNA sequences of 100 pancreatic tumors were identified and analyzed.

DNA is a long-chain molecule whose chemical building blocks, called nucleotides, form the genetic code. An organism's DNA is called its genome, which is like an instruction manual for building that organism. In humans, each cell has tightly packed DNA molecules formed around 100,000,000 nucleotides, contained in 23 pairs of chromosomes.

Genes are a subset of a cell's DNA and are formed by DNA. They also contain various instructions for producing proteins, the organism's building blocks, and are, in a sense, the workhorses of cells. Only a small part of our DNA forms genes; the remaining sections contain other instructions about how genes are activated or inactivated.

During cellular functioning, various disruptions may occur in DNA, such as copying errors during cell division. The resulting mutations may cause genetic chaos by creating incorrect genes. These new genes may cause the mechanisms they control to activate or deactivate at the wrong time.

According to the study, pancreatic cancer can be divided into 4 subtypes based on the type, location, and frequency of DNA rearrangements. These were called stable, locally rearranged, scattered, and unstable.

Despite years of pancreatic cancer treatment research, many barriers to finding new treatments remain. Some mutations identified during this study may be targets for new drugs. This highly important study sheds light on genetic errors caused by chaotic chromosomal rearrangements that underlie the disease and offers opportunities for more personalized treatment.

Patients with the pancreatic cancer subtype called "unstable" may benefit from platinum-based drugs.

The research team also obtained evidence that platinum-based chemotherapy drugs widely used for testicular, ovarian, and other cancers might also work in pancreatic cancer patients.

Until now, platinum therapies have produced conflicting results in pancreatic cancer. However, this study suggests that patients with the unstable subtype may benefit substantially from platinum-based drugs.

Studies such as this, fruits of the Human Genome Project whose first phase was declared complete on 26 June 2000 with the phrase "the most beautiful day of all time," have already begun changing our view of cancer. The project is expected to profoundly transform medicine by revolutionizing the diagnosis and treatment of all diseases, from cancer to depression and even aging.